GSK Lung Cancer Breakthrough
GSK secures early FDA approval for Jideytro, its first lung cancer drug from Nuvalent acquisition.
Anonymous
Key Points
1
FDA granted Breakthrough Therapy and Orphan Drug designations to Jideytro (zidesamtinib), accelerating regulatory review and potentially speeding patient access.
2
Durability of response in ARROS-1 was notable: among 117 patients, 82% of responders maintained response at six months and 69% at 12 months.
3
ROS1 mutations are present in about 2% of non-small cell lung cancer cases, highlighting the relatively small, targeted market for ROS1 inhibitors like Jideytro.
GSK has earned its first-ever FDA approval for a lung cancer drug. The agency cleared Jideytro (zidesamtinib) for adults with ROS1-positive non-small cell lung cancer (NSCLC) who have already tried another ROS1 inhibitor. The approval came ahead of its September 18 target date, according to BioPharma Dive.
The drug came to GSK through its $10.6 billion acquisition of Nuvalent — one of the biggest biotech deals of the year. Fierce Pharma noted the quick turnaround makes Jideytro the first commercial lung cancer drug in GSK's history.
ARROS-1 Trial Data Drove the Fast Approval
The FDA based its decision on results from the ARROS-1 clinical trial. Among 117 patients, the drug showed a 44% objective response rate. That means nearly half of patients saw their tumors shrink, according to MedCity News.
The durability of results also stood out. Among patients who responded, 82% still had a response at six months. At 12 months, 69% maintained that response. The FDA also granted the drug Breakthrough Therapy and Orphan Drug designations. These labels can speed up review and expand access for patients.
Jideytro Targets Tumors That Resist Older Drugs
ROS1-positive NSCLC is a specific subtype driven by a gene mutation. It affects roughly 2% of all non-small cell lung cancer cases. That is a small patient population, but one with limited options after first-line treatment fails.
Jideytro is designed as a next-generation ROS1 inhibitor. It is built to be more selective than older drugs. It can also cross the blood-brain barrier, which helps treat brain metastases — tumors that spread to the brain. This sets it apart from earlier therapies like Xalkori and Rozlytrek, according to Fierce Pharma.
A $10.6 Billion Bet on GSK's Oncology Comeback
GSK acquired Nuvalent in 2025 in one of pharma's biggest deals of the year. The company paid $10.6 billion. Jideytro was the lead asset, and its fast FDA clearance shows an early return on that investment, London Insider reported.
CEO Luke Miels has made rebuilding GSK's cancer drug pipeline a top priority. Jideytro is just the start. Another Nuvalent drug, neladalkib, is also moving through development. GSK's leadership called this approval a milestone in that broader push to become a serious oncology player.
Competitive Market Could Limit Jideytro's Sales Upside
Despite the approval, Jideytro enters a crowded space. ROS1 inhibitors like Pfizer's Xalkori and Genentech's Rozlytrek are already on the market. The patient pool is small — only about 2% of NSCLC cases carry the ROS1 mutation — which caps the drug's total market size, according to Myrtle Beach Online.
Sales forecasts remain uncertain. GSK will need to show doctors that Jideytro's brain penetration and resistance-fighting profile justify switching from existing options. How quickly it captures market share will be a key test of GSK's growing oncology ambitions.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
16
Articles
25
Reach
41
A
AnonymousAuthor